PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
49.00%
EBIT growth above 1.5x AXSM's 23.84%. David Dodd would confirm if core operations or niche positioning yield superior profitability.
-9.04%
Negative operating income growth while AXSM is at 35.57%. Joel Greenblatt would press for urgent turnaround measures.
48.96%
Net income growth above 1.5x AXSM's 19.26%. David Dodd would check if a unique moat or cost structure secures superior bottom-line gains.
53.59%
EPS growth above 1.5x AXSM's 20.49%. David Dodd would review if superior product economics or effective buybacks drive the outperformance.
51.99%
Diluted EPS growth above 1.5x AXSM's 20.49%. David Dodd would see if there's a robust moat protecting these shareholder gains.
10.21%
Share count expansion well above AXSM's 1.17%. Michael Burry would question if management is raising capital unnecessarily or is over-incentivizing employees with stock.
6.42%
Diluted share count expanding well above AXSM's 1.17%. Michael Burry would fear significant dilution to existing owners' stakes.
No Data
No Data available this quarter, please select a different quarter.
-59.54%
Negative OCF growth while AXSM is at 25.25%. Joel Greenblatt would demand a turnaround plan focusing on real cash generation.
-60.23%
Negative FCF growth while AXSM is at 25.25%. Joel Greenblatt would demand improved cost control or more strategic capex discipline.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-7534.43%
Both show negative 10Y OCF/share CAGR. Martin Whitman would question if the entire market or product set is shrinking or too capital-intensive.
-15675.30%
Both show negative mid-term OCF/share growth. Martin Whitman might suspect a challenged environment or large capital demands for both.
-5709.37%
Negative 3Y OCF/share CAGR while AXSM stands at 23.58%. Joel Greenblatt would demand an urgent turnaround in the firm’s cost or revenue drivers.
-6744.35%
Both face negative decade-long net income/share CAGR. Martin Whitman would suspect a shrinking or highly disrupted sector.
-20067.21%
Both exhibit negative net income/share growth over five years. Martin Whitman would suspect a challenging environment for the entire niche.
-6838.40%
Negative 3Y CAGR while AXSM is 11.48%. Joel Greenblatt might call for a short-term turnaround strategy or cost realignment.
No Data
No Data available this quarter, please select a different quarter.
530.49%
Positive 5Y equity/share CAGR while AXSM is negative. John Neff might see a clear edge in retaining earnings or managing capital better.
431.75%
3Y equity/share CAGR above 1.5x AXSM's 280.02%. David Dodd verifies the company’s short-term capital management far exceeds the competitor’s pace.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-29.38%
Negative asset growth while AXSM invests at 7.23%. Joel Greenblatt checks if the competitor might capture more market share unless our returns remain higher.
-71.36%
We have a declining book value while AXSM shows 35.76%. Joel Greenblatt sees a fundamental disadvantage in net worth creation vs. the competitor.
-100.00%
We’re deleveraging while AXSM stands at 2.81%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
52.82%
R&D growth drastically higher vs. AXSM's 10.62%. Michael Burry fears near-term margin erosion unless breakthroughs are imminent.
-14.04%
We cut SG&A while AXSM invests at 7.86%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.